NCT04813380View on ClinicalTrials.gov

Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients as Biomarkers for Efficacy of Sublingual Immunotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

September 10, 2022

Study Completion Date

October 10, 2022

Conditions
Effects of Immunotherapy
Interventions
OTHER

Sublingual immunotherapy

Sublingual immunotherapy give to allergic rhinitis patients for treatment

Trial Locations (1)

44511

Fatma Zohry Kamel Khater, Zagazig

All Listed Sponsors
lead

Zagazig University

OTHER_GOV

NCT04813380 - Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients as Biomarkers for Efficacy of Sublingual Immunotherapy | Biotech Hunter | Biotech Hunter